Lipoplatin™ monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 86-90

  Ravaioli, Alberto ^a   Papi, M ^a   Pasquini, E ^b   Marangolo, M ^c   Rudnas, B ^a   Fantini, M ^a   Nicoletti, S V L ^a   Drudi, F ^a   Panzini, I ^a   Tamburini, E ^a   Gianni, L ^a   Pasini, G ^a  

^a INFERMI HOSPITAL   (Italy)

^b Cervesi Hospital   (Italy)

^c SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Lung cancer; Platinum analogues; Second line chemo therapy; Toxicity

Indexed keywords

CISPLATIN; LIPOPLATIN; LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TOXICITY TESTING; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 63049096285     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.1.86     Document Type: Article

References (30)

1. Rosenberg B, Van Camp L, Trosko JE, et al. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222: 385-386.
2. Ball D, Smith J, Wirth A, et al. Failure of T stage to predict survival in patients with non-small cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002; 54: 1007-1013.
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
4. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002; 87: 825-833.
5. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (Review). Oncol Rep 2004, 11: 559-595.
6. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228-244.
7. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23: 460-464.
8. Townsend DM, Deng M, Zhang L, et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14: 1-10.
9. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Ascad Sci 1999; 884: 15-18.
10. Caraceni A, Martini C, Spatti G, et al. Recovering optic neuritis during systematic cisplatin and carboplatin chemotherapy. Acta Neurol Scand 1997; 96: 260-261.
11. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006; 44: 1173-1183.
12. Waters JS, O'Brien ME. The case for introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer 2002; 87: 481-490.
13. Stathopoulos GP, Boulikas T, Vougiokas M, et al. Pharmacokinetics and adverse reactions of new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 2005; 13: 589-595.
14. Boulikas T. Low toxicity and activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12: 3-12.
15. Boulikas T, Stathopoulos GP, Volakakis N, et al. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25: 3031-3039.
16. Bandak S, Goren D, Horowitz A, et al. A pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 1990; 10: 911-920.
17. Devarajan P, Tarabishi R, Mishra J, et al. Low renal toxicity of Lipoplatin compared to Cisplatin in animals. Anticancer Res 2004; 24: 2193-2200.
18. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10: 1663-1682.
19. Jehn CF, Boulikas T, Kourvetaris, et al. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007; 27: 471-475.
20. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Liposomial cisplatin with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006; 15: 1201-1204.
21. Minko T, Pakunlu RI, Wang Y. New generation of liposomial drugs of cancer. Anticancer Agents Med Clin 2006; 6: 537-552.
22. Gormley P, Bull J, LeRoy A, et al. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 1979; 25:351.
23. Belt R, Himmelstein K, Patton T, et al. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1979; 63: 1515.
24. Shepherd FA, Kancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
25. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1596.
26. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cncer. Clin Ther 2005; 27: 1513-1534.
27. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in Lung Cancer: Molecular and Clinical predictors of Outcome. N Engl J Med 2005; 353: 133-144.
28. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, Anderson H, Ranson M. Phase II study of SPI-77(stericallystabilised liposomal cisplatin) in advanced non-small-cell lung cancer.BJC 2006;95:822-828.
29. De Mario MD, Vogelzang NJ, Janisch L., Tonda M., Amantea MA., Pendyala L., Ratain LJ. A phase I study of liposome-formulated Cisplatin (SPI-77R) given every 3 weeks in patients with advanced cancer (meeting abstract), Abstract no.883, ASCO Annual Meeting 1998.
30. Harrington KJ, Lewansky CR, Northcote AB, Whittaker J., Wellbank H, Vile RG, Peters AM, Stewart JS, Phase I-II of pegylated liposomal Cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol. 2001; 12:493-6.